Innate Pharma appoints Nicolai Wagtmann Chief Scientific Officer

• Nicolai Wagtmann, previously Vice-President R&D at Novo Nordisk A/S, generated and developed a portfolio of therapeutic antibodies for the treatment of cancer and inflammatory diseases
• François Romagné to lead CIMTECH and join Innate Pharma’s Scientific Advisory Board

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announces the appointment of Nicolai Wagtmann as Chief Scientific Officer. His appointment to the Executive Board will be proposed at the next Supervisory board.

Nicolai Wagtmann joins Innate Pharma from Novo Nordisk A/S where he was Vice-President R&D and Head of Inflammation Biology. Nicolai Wagtmann is a pioneer of pharmacological approaches targeting innate immunity lymphocytes both in immuno-oncology and in inflammation. His research, initiated in academia, was developed in industry through the research collaboration between Innate Pharma and Novo Nordisk A/S.